Clinical trials have certified that sorafenib and lenvatinib are multikinase inhibitors, regorafenib and cabozantinib are tyrosine kinase inhibitors, and ramucirumab is a monoclonal antibody, and all of them target the factors of the VEGF axis to block tube formation in hepatocellular cancer [158]. Here, VEGFA is linked to hepatocellular carcinoma.